[2-(2,5-dimethylphenyl)-imidazol-1-yl]pyridin-3-ylmethanone | 1335144-81-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: [2-(2,5-dimethylphenyl)-imidazol-1-yl]pyridin-3-ylmethanone
• 英文别名: [2-(2,5-Dimethylphenyl)imidazol-1-yl]-pyridin-3-ylmethanone
• CAS: 1335144-81-4
• 化学式: C₁₇H₁₅N₃O
• 分子量: 277.326
• InChiKey: QAOOSLWRHFFTDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  47.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  烟酸 在 氯化亚砜 作用下， 以 乙醚 为溶剂， 反应 24.0h， 生成 [2-(2,5-dimethylphenyl)-imidazol-1-yl]pyridin-3-ylmethanone
  参考文献：
  名称：

  Synthesis, antimicrobial and antimycobacterial evaluation of [2-(substituted phenyl)-imidazol-1-yl]-pyridin-3-yl-methanones

  摘要：

  A series of [2-(substituted phenyl)-imidazol-1-yl]-pyridin-3-yl-methanones (1-11) were synthesized and screened for their antimicrobial and antimycobacterial activities. Further, a series of [2-(substituted phenyl)-benzimidazol-1-yl]-pyridin-3-yl-methanones (12-20) reported in our earlier study was also screened for their antimycobacterial activity. The antimycobacterial activity results indicated that [2-(4-Nitro-phenyl)-imidazol-1-yl]-pyridin-3-yl-methanone (8, minimum inhibitory concentration [MIC] = 3.13 mu g) was equipotent as standard drug ciprofloxacin and [2-(4-Nitrophenyl)-benzimidazol-1-yl]-pyridin-3-yl-methanone (16, MIC = 1.56 mu g) was equipotent as standard drug ethambutol. The results of antimicrobial screening demonstrated that 2-[1-(Pyridine-3-carbonyl)-1H-imidazol-2-yl]-benzoic acid (compound 11, MIC = 0.002 mu g) was two times more effective than standard drug ciprofloxacin (MIC = 0.004 mu g) against tested bacterial strains and [2-(2,5-Dimethyl-phenyl)-imidazol-1-yl]-pyridin-3-yl-methanone (compound 3, MIC = 0.005 mu g) was equipotent to the reference compound, fluconazole against tested fungal strains.

  DOI：

  10.3109/14756366.2010.548331

文献信息

• Synthesis, antimicrobial and antimycobacterial evaluation of [2-(substituted phenyl)-imidazol-1-yl]-pyridin-3-yl-methanones
  作者：Balasubramanian Narasimhan、Deepika Sharma、Pradeep Kumar、Perumal Yogeeswari、Dharmarajan Sriram

  DOI：10.3109/14756366.2010.548331

  日期：2011.10.1

  A series of [2-(substituted phenyl)-imidazol-1-yl]-pyridin-3-yl-methanones (1-11) were synthesized and screened for their antimicrobial and antimycobacterial activities. Further, a series of [2-(substituted phenyl)-benzimidazol-1-yl]-pyridin-3-yl-methanones (12-20) reported in our earlier study was also screened for their antimycobacterial activity. The antimycobacterial activity results indicated that [2-(4-Nitro-phenyl)-imidazol-1-yl]-pyridin-3-yl-methanone (8, minimum inhibitory concentration [MIC] = 3.13 mu g) was equipotent as standard drug ciprofloxacin and [2-(4-Nitrophenyl)-benzimidazol-1-yl]-pyridin-3-yl-methanone (16, MIC = 1.56 mu g) was equipotent as standard drug ethambutol. The results of antimicrobial screening demonstrated that 2-[1-(Pyridine-3-carbonyl)-1H-imidazol-2-yl]-benzoic acid (compound 11, MIC = 0.002 mu g) was two times more effective than standard drug ciprofloxacin (MIC = 0.004 mu g) against tested bacterial strains and [2-(2,5-Dimethyl-phenyl)-imidazol-1-yl]-pyridin-3-yl-methanone (compound 3, MIC = 0.005 mu g) was equipotent to the reference compound, fluconazole against tested fungal strains.